当前位置： SCI文献检索 > CYTOTHERAPY期刊下所有文献 > Ex vivo expansion of umbilical cord blood.

Ex vivo expansion of umbilical cord blood.

Abstract：

:The efficacy of cord blood (CB) transplantation is limited by the low cell dose available. Low cell doses at transplant are correlated with delayed engraftment, prolonged neutropenia and thrombocytopenia and elevated risk of graft failure. To potentially improve the efficacy of CB transplantation, approaches have been taken to increase the cell dose available. One approach is the transplantation of multiple cord units, another the use of ex vivo expansion. Evidence for a functional and phenotypic heterogeneity exists within the HSC population and one concern associated with ex vivo expansion is that the expansion of lower 'quality' hematopoietic progenitor cells (HPC) occurs at the expense of higher 'quality' HPC, thereby impacting the reserve of the graft. There is evidence that this is a valid concern while other evidence suggests that higher quality HPC are preserved and not exhausted. Currently, ex vivo expansion processes include: (1) liquid expansion: CD34+ or CD133+ cells are selected and cultured in medium containing factors targeting the proliferation and self-renewal of primitive hematopoietic progenitors; (2) co-culture expansion: unmanipulated CB cells are cultured with stromal components of the hematopoietic microenvironment, specifically mesenchymal stem cells (MSC), in medium containing growth factors; and (3) continuous perfusion: CB HPC are cultured with growth factors in 'bioreactors' rather than in static cultures. These approaches are discussed. Ultimately, the goal of ex vivo expansion is to increase the available dose of the CB cells responsible for successful engraftment, thereby reducing the time to engraftment and reducing the risk of graft failure.

journal_name

Cytotherapy

journal_title

Cytotherapy

authors

Robinson S,Niu T,de Lima M,Ng J,Yang H,McMannis J,Karandish S,Sadeghi T,Fu P,del Angel M,O'Connor S,Champlin R,Shpall E

doi

10.1080/14653240510027172

keywords:

subject

Has Abstract

pub_date

2005-01-01 00:00:00

pages

243-50

issue

3

eissn

1465-3249

issn

1477-2566

pii

W52W73M60441237K

journal_volume

7

pub_type

杂志文章,评审

相关文献

CYTOTHERAPY文献大全
  • IL-2-activated cord blood mononuclear cells.

    abstract：BACKGROUND:[corrected] Recent findings in cord blood (CB) research indicate the potential clinical usefulness of IL-2-activated CB in eradication of minimal malignant residual disease after hematopoietic stem cell transplantation. This feasible approach to immunotherapy merits further pre-clinical investigations using ...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240500319184

    authors： Derzic S,Slone V,Sender L

    更新日期：2005-01-01 00:00:00

  • Factors modulating circulation of hematopoietic progenitor cells in cord blood and neonates.

    abstract：BACKGROUND:Hematopoietic progenitor cells (HPC) circulate at high levels at birth and disappear rapidly afterwards, but the underlying mechanism it is not known. The aim of this study was to assess circulating HPC in cord blood at different gestational ages and shortly after birth and concomitantly study the biologic m...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240802499148

    authors： Gonzalez S,Amat L,Azqueta C,Madrigal JA,Laïlla JM,Garcia J,Querol S

    更新日期：2009-01-01 00:00:00

  • T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells.

    abstract：BACKGROUND AIMS:Chimeric antigen receptors (CARs) designed for adoptive immunotherapy need to achieve two functions: antigen recognition and triggering of the lytic machinery of reprogrammed effector cells. Cytotoxic T cells have been engineered with FcγRIII (CD16) chimeric molecules to be redirected against malignant ...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2015.10.014

    authors： D'Aloia MM,Caratelli S,Palumbo C,Battella S,Arriga R,Lauro D,Palmieri G,Sconocchia G,Alimandi M

    更新日期：2016-02-01 00:00:00

  • Developing a co-culture system for effective megakaryo/thrombopoiesis from umbilical cord blood hematopoietic stem/progenitor cells.

    abstract：BACKGROUND AIMS:Platelet transfusion can be a life-saving procedure in different medical settings. Thus, there is an increasing demand for platelets, of which shelf-life is only 5 days. The efficient ex vivo biomanufacturing of platelets would allow overcoming the shortages of donated platelets. METHODS:We exploited a...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2014.12.010

    authors： Hatami J,Andrade PZ,Alves de Matos AP,Djokovic D,Lilaia C,Ferreira FC,Cabral JM,da Silva CL

    更新日期：2015-04-01 00:00:00

  • Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.

    abstract：BACKGROUND:The aim of this study was to investigate preservation of anti-leukemic activity and protection from opportunistic infections after transplantation of allogeneic + cells in patients with hematologic malignancies and bad prognosis. Methods Thirty-three patients [median age 42 years, range 23-55 years, diagnosi...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240410005375

    authors： Kobbe G,Fenk R,Neumann F,Bernhardt A,Steidl U,Kondakci M,Graef T,Aivado M,Vaupel M,Huenerlituerkoglu AN,Kronenwett R,Pape H,Hildebrand B,Germing U,Haas R

    更新日期：2004-01-01 00:00:00

  • Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

    abstract：BACKGROUND AIMS:The Quantum® Cell Expansion System (Quantum; Terumo BCT, Inc, Lakewood, CO, USA) is a novel hollow fiber-based device that automates and closes the cell culture process, reducing labor intensive tasks such as manual cell culture feeding and harvesting. The manual cell selection and expansion processes f...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2013.05.024

    authors： Jones M,Varella-Garcia M,Skokan M,Bryce S,Schowinsky J,Peters R,Vang B,Brecheisen M,Startz T,Frank N,Nankervis B

    更新日期：2013-11-01 00:00:00

  • In vitro expression of erythropoietin by transfected human mesenchymal stromal cells.

    abstract：BACKGROUND:Mesenchymal stromal cells (MSC) are pluripotent progenitor cells that can be found in human bone marrow (BM). These cells have low immunogenicity and could suppress alloreactive T-cell responses. In the current study, MSC were tested for their capacity to carry and deliver the erythropoietin (EPO) gene in vi...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240701816996

    authors： Mok PL,Cheong SK,Leong CF,Othman A

    更新日期：2008-01-01 00:00:00

  • A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.

    abstract：:Regulatory T cells (Tregs) play a fundamental role in the maintenance of self-tolerance and immune homeostasis. Defects in Treg function and/or frequencies have been reported in multiple disease models. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting upper and lower motor neur...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2016.06.012

    authors： Alsuliman A,Appel SH,Beers DR,Basar R,Shaim H,Kaur I,Zulovich J,Yvon E,Muftuoglu M,Imahashi N,Kondo K,Liu E,Shpall EJ,Rezvani K

    更新日期：2016-10-01 00:00:00

  • Neural stem cells transplanted to the subretinal space of rd1 mice delay retinal degeneration by suppressing microglia activation.

    abstract：BACKGROUND AIMS:Retinal degeneration (RD) is an inherited eye disease characterized by irreversible photoreceptor loss. Conventionally, the activation of the resident microglia is secondary to the disease. Stem cell-based therapy has recently made rapid progress in treating RD. Although it has been demonstrated that th...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2016.03.001

    authors： Li Z,Zeng Y,Chen X,Li Q,Wu W,Xue L,Xu H,Yin ZQ

    更新日期：2016-06-01 00:00:00

  • Summary of the National Institute of Standards and Technology and US Food And Drug Administration cell counting workshop: Sharing practices in cell counting measurements.

    abstract：:The emergence of cell-based therapeutics has increased the need for high-quality, robust and validated measurements for cell characterization. Cell count, being one of the most fundamental measures for cell-based therapeutics, now requires increased levels of measurement confidence. The National Institute of Standards...

    journal_title：Cytotherapy

    pub_type： 杂志文章,评审

    doi：10.1016/j.jcyt.2018.03.031

    authors： Lin-Gibson S,Sarkar S,Elliott JT

    更新日期：2018-06-01 00:00:00

  • Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension.

    abstract：BACKGROUND AIMS:Endothelial apoptosis underlies the pathophysiology of pulmonary arterial hypertension (PAH). Some factors/cytokines released by endothelial progenitor cells (EPC) have been revealed as potent inhibitors of apoptosis. The aim of this study was to investigate the effects of EPC on pulmonary microvascular...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240902960460

    authors： Xia L,Fu GS,Yang JX,Zhang FR,Wang XX

    更新日期：2009-01-01 00:00:00

  • Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.

    abstract：BACKGROUND AIMS:Imatinib (IM), a tyrosine kinase inhibitor targeting the BCR-ABL oncoprotein, remains a major therapeutic strategy for patients with chronic myelogenous leukemia (CML). However, IM resistance is still a challenge in the treatment of CML. Recently, it was reported that exosomes (Exo) were involved in dru...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2017.11.006

    authors： Liu Y,Song B,Wei Y,Chen F,Chi Y,Fan H,Liu N,Li Z,Han Z,Ma F

    更新日期：2018-02-01 00:00:00

  • Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study.

    abstract：BACKGROUND AIMS:Mesenchymal stromal cell (MSC) transplantation has immerged as promising therapeutic approach to treat spinal cord injury (SCI). In this pilot study, we investigated the safety of intrathecal injection of autologous bone marrow-derived MSCs in nine patients with SCI. METHODS:Patients with complete SCI ...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2016.01.004

    authors： Satti HS,Waheed A,Ahmed P,Ahmed K,Akram Z,Aziz T,Satti TM,Shahbaz N,Khan MA,Malik SA

    更新日期：2016-04-01 00:00:00

  • Human amniotic mesenchymal stromal cell transplantation improves endometrial regeneration in rodent models of intrauterine adhesions.

    abstract：BACKGROUND AIMS:Intrauterine adhesion (IUA) is a common uterine cavity disease characterized by the unsatisfactory regeneration of damaged endometria. Recently, stem cell transplantation has been proposed to promote the recovery process. Here we investigated whether human amniotic mesenchymal stromal cells (hAMSCs), a ...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2017.02.003

    authors： Gan L,Duan H,Xu Q,Tang YQ,Li JJ,Sun FQ,Wang S

    更新日期：2017-05-01 00:00:00

  • Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study.

    abstract：BACKGROUND:Patients with ulcerative colitis (UC) have elevated/activated myeloid lineage leucocytes and may respond favorably to adsorptive granulocyte/monocyte apheresis (GMA). However, there are patients who respond well to GMA, and patients who do not benefit. Therefore, predictive factors of GMA efficacy need to be...

    journal_title：Cytotherapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.jcyt.2015.02.007

    authors： Yokoyama Y,Watanabe K,Ito H,Nishishita M,Sawada K,Okuyama Y,Okazaki K,Fujii H,Nakase H,Masuda T,Fukunaga K,Andoh A,Nakamura S

    更新日期：2015-05-01 00:00:00

  • Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells.

    abstract：BACKGROUND AIMS:Stem cell therapy for liver diseases has recently emerged as a promising alternative to liver transplantation. Eligible cells should have an appropriate immunophenotype. The aim of the present study was to define the immunological profile of two human liver-derived mesenchymal stromal cell populations, ...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2014.10.001

    authors： Raicevic G,Najar M,Najimi M,El Taghdouini A,van Grunsven LA,Sokal E,Toungouz M

    更新日期：2015-02-01 00:00:00

  • Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys.

    abstract：BACKGROUND:Transplantation of mesenchymal stem cells (MSC) in rodent models has proved to be an effective therapeutic approach for spinal cord injury (SCI). However, further studies in primate models are still needed before clinical application of MSC to patients. METHODS:MSC were isolated from rhesus monkey BM and in...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240600760808

    authors： Deng YB,Liu XG,Liu ZG,Liu XL,Liu Y,Zhou GQ

    更新日期：2006-01-01 00:00:00

  • Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status.

    abstract：:Not all patients with Hodgkin's disease (HD) respond to standard chemotherapy and/or radiation, and hematopoietic stem-cell transplantation has been gaining increasing acceptance in the management of HD. Phase II and, to a lesser extent, phase III studies of high-dose chemotherapy and autologous stem cell transplantat...

    journal_title：Cytotherapy

    pub_type： 杂志文章,评审

    doi：10.1080/146532402320219754

    authors： Anderlini P

    更新日期：2002-01-01 00:00:00

  • Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice.

    abstract：BACKGROUND AIMS:Existing treatments have limited success in modifying the course of peripheral artery disease, which may eventually lead to limb-threatening ulcers and amputation. Cellular therapies have the potential to provide a new treatment option for this condition, but isolation of cells by conventional means has...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2015.10.013

    authors： Koch JM,D'Souza SS,Schwahn DJ,Dixon I,Hacker TA

    更新日期：2016-02-01 00:00:00

  • Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences.

    abstract：BACKGROUND:Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. METHODS:Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/146532402761624700

    authors： Khuu HM,Cowley H,David-Ocampo V,Carter CS,Kasten-Sportes C,Wayne AS,Solomon SR,Bishop MR,Childs RM,Read EJ

    更新日期：2002-01-01 00:00:00

  • Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences.

    abstract：BACKGROUND:Retroviral vectors are regularly used to transduce stem cells and their derivatives for experimental and therapeutic purposes. Because these vectors integrate semi-randomly into the cellular genome, analysis of integranated retroviral DNA/host cell DNA junctions (IHJ) facilitates clonality studies of engraft...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240802192636

    authors： Pule MA,Rousseau A,Vera J,Heslop HE,Brenner MK,Vanin EF

    更新日期：2008-01-01 00:00:00

  • Mesenchymal stromal cells from donors varying widely in age are of equal cellular fitness after in vitro expansion under hypoxic conditions.

    abstract：BACKGROUND AIMS:Mesenchymal stromal cells (MSC) are gaining in popularity as an experimental therapy for a number of conditions that often require expansion ex vivo prior to use. Data comparing clinical-grade MSC from various ages of donors are scant. We hypothesized that MSC from older donors may display differences i...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.3109/14653249.2010.509394

    authors： Lund TC,Kobs A,Blazar BR,Tolar J

    更新日期：2010-12-01 00:00:00

  • Differential properties of human stromal cells from bone marrow, adipose, liver and cardiac tissues.

    abstract：BACKGROUND AIMS:Mesenchymal stromal cells (MSCs), derived from several tissues including bone marrow and adipose tissue, are being evaluated in clinical trials for a range of diseases. Virtually all tissues of the body contain stromal cells, yet it is unknown whether these sources are similar in phenotype and function....

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2015.07.009

    authors： Kellner J,Sivajothi S,McNiece I

    更新日期：2015-11-01 00:00:00

  • Placental mesenchymal stromal cells induced into neurotrophic factor-producing cells protect neuronal cells from hypoxia and oxidative stress.

    abstract：BACKGROUND AIMS:Mesenchymal stromal cells (MSC) may be useful in a range of clinical applications. The placenta has been suggested as an abundant, ethically acceptable, less immunogenic and easily accessible source of MSC. The aim of this study was to evaluate the capacity of induced placental MSC to differentiate into...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.3109/14653249.2011.613928

    authors： Yust-Katz S,Fisher-Shoval Y,Barhum Y,Ben-Zur T,Barzilay R,Lev N,Hod M,Melamed E,Offen D

    更新日期：2012-01-01 00:00:00

  • Development of standardized cell culture conditions for tumor cells with potential clinical application.

    abstract：BACKGROUND:Tumor cell lines have enormous value for the study of different aspects of cancer biology and have also recently gained great importance in autologous cell-based anti-tumor therapies. However, the use of these cells is still limited because in vitro growth is hampered by suboptimal culture conditions and cur...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1080/14653240701385836

    authors： Stadler G,Wieser M,Steindl F,Grillari J,Katinger H,Pfragner R,Voglauer R

    更新日期：2007-01-01 00:00:00

  • Simplified process for the production of anti-CD19-CAR-engineered T cells.

    abstract：BACKGROUND AIMS:Adoptive immunotherapy with the use of chimeric antigen receptor (CAR)-engineered T cells specific for CD19 has shown promising results for the treatment of B-cell lymphomas and leukemia. This therapy involves the transduction of autologous T cells with a viral vector and the subsequent cell expansion. ...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2013.06.003

    authors： Tumaini B,Lee DW,Lin T,Castiello L,Stroncek DF,Mackall C,Wayne A,Sabatino M

    更新日期：2013-11-01 00:00:00

  • Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit.

    abstract：BACKGROUND AIMS:Enumeration of CD34(+) cells in leukocyte-rich cell suspensions is important for clinical decision-making in stem cell transplantation. Single-platform flow cytometry assays offer the significant advantages of speed and reproducibility, and have therefore become the gold standard in stem cell enumeratio...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.3109/14653249.2010.529894

    authors： Dauber K,Becker D,Odendahl M,Seifried E,Bonig H,Tonn T

    更新日期：2011-04-01 00:00:00

  • Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products.

    abstract：BACKGROUND:Cell therapy has been proposed as a salvage limb procedure in critical limb ischemia (CLI). In spite of the fact that clinical trials found some efficacy, the mechanism of action remains elusive. The objective of this study was to characterize two autologous cell therapy products (CTPs) obtained from patient...

    journal_title：Cytotherapy

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.jcyt.2016.10.013

    authors： Tournois C,Pignon B,Sevestre MA,Al-Rifai R,Creuza V,Poitevin G,François C,Nguyen P

    更新日期：2017-02-01 00:00:00

  • Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer.

    abstract：BACKGROUND:DS60 is a novel buoyant density solution, whose density has been adjusted to enrich PBSC from subjects who have been mobilized with cytokines alone, or cytokines plus chemotherapy. This report describes the use of BDS60 to enrich autologous PBSC that were used for hematological reconstitution after myeloabla...

    journal_title：Cytotherapy

    pub_type： 临床试验,杂志文章

    doi：10.1080/146532400539134

    authors： Laport GG,Valone FH,Zimmerman TM,Grinblatt DL,Van Vlasselaer P,Still BJ,Williams SF

    更新日期：2000-01-01 00:00:00

  • Impact of local injection of brain-derived neurotrophic factor-expressing mesenchymal stromal cells (MSCs) combined with intravenous MSC delivery in a canine model of chronic spinal cord injury.

    abstract：BACKGROUND AIMS:The microenvironment of the chronically injured spinal cord does not allow for axonal regeneration due to glial scarring. To ameliorate this, several therapeutic strategies have been used. We investigated whether combined transplantation of chondroitinase ABC (chABC) and mesenchymal stromal cells (MSCs)...

    journal_title：Cytotherapy

    pub_type： 杂志文章

    doi：10.1016/j.jcyt.2016.09.014

    authors： Lee SH,Kim Y,Rhew D,Kim A,Jo KR,Yoon Y,Choi KU,Jung T,Kim WH,Kweon OK

    更新日期：2016-10-28 00:00:00